--- title: "InflaRx prices $150,000,000 share offering at $2.00" url: "https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-05-06" section: "Financings" tickers: "NASDAQ:IFRX" source: "https://www.sec.gov/Archives/edgar/data/1708688/000114036126019288/ny20072539x1_424b5.htm" summary: "InflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026." --- By the aibio.space news desk. Sources - [InflaRx N.V. 424B5 (2026-05-06)](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019288/ny20072539x1_424b5.htm) - [InflaRx N.V. 424B5 (2026-05-07)](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019440/ny20072539x2_424b5.htm) - [InflaRx N.V. 6-K (2026-05-07)](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019534/ef20072665_6k.htm) [IFRX](https://aibio.space/companies/inflarx-n-v/) 2026-05-06 # InflaRx prices $150,000,000 share offering at $2.00 and closes it a day later Tickers [IFRX](https://aibio.space/companies/inflarx-n-v/) InflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026. ## Key facts - **Company**: InflaRx N.V. (NASDAQ: IFRX) - **News type**: Financings - **Primary source**: [InflaRx N.V. 424B5 (2026-05-06)](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019288/ny20072539x1_424b5.htm) *Planning on a whiteboard. Photo: Startup Stock Photos, CC0, via StockSnap. The picture shows the field, not the companies named.* InflaRx N.V. agreed on May 6, 2026 to sell 75,000,000 ordinary shares at $2.00 each, a total public offering price of $150,000,000. The offering closed on May 7, 2026. The ordinary shares, with a nominal value of €0.12 per share, trade on the Nasdaq Global Market under the symbol IFRX. The last sale price before the deal was $1.97 on May 5, 2026, so the offering price sat above that level. ## Pricing and what the company keeps The underwriting discount is $0.12 per share, or $9,000,000 in total. Proceeds to InflaRx before expenses are $1.88 per share, or $141,000,000. The final prospectus supplement estimates net proceeds of about $140.5 million after the discount and estimated offering expenses. The Form 6-K describes gross proceeds of approximately $150 million and says the shares were sold under an effective shelf registration statement. The prospectus gives that registration as No. 333-273058, with a base prospectus dated July 11, 2023. The company says it intends to use the net proceeds to advance its pipeline and for working capital and general corporate purposes. The prospectus says management has broad discretion over how the money is spent and that investors may not agree with the choices. The prospectus counts 72,292,859 ordinary shares outstanding as of March 31, 2026. That would rise to 147,292,859 after the offering. It also lists 13,926,245 shares issuable under option awards in the 2017 long-term incentive plan, 888,632 vested options under the 2016 plan, 148,433 vested options under the 2012 plan and 6,750,000 shares issuable on pre-funded warrants. The company says it has issued no shares under its at-the-market program since March 31, 2026. ## Underwriters and counsel Guggenheim Securities, LLC is lead book-running manager and acts as representative of the underwriters under the underwriting agreement dated May 6, 2026. Oppenheimer & Co. and LifeSci Capital are book-running managers. Raymond James and Needham & Company are co-lead managers, and H.C. Wainwright & Co. and Lucid Capital Markets are co-managers. The prospectus names no financial advisor. NautaDutilh N.V. passes on the validity of the shares under Dutch law for InflaRx, and its opinion is filed as Exhibit 5.1 to the 6-K. Kirkland & Ellis LLP, of New York, passes on U.S. federal and New York law matters for the company. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., of Boston, is counsel to the underwriters on U.S. federal and New York law. InflaRx has agreed to indemnify the underwriters against certain liabilities, including those under the Securities Act of 1933. ## Cash, runway and the company's own claims As of March 31, 2026, the company reported total funds of about EUR 39.7 million. That was made up of EUR 15.0 million in cash and cash equivalents and EUR 24.7 million in marketable securities. The capitalization table shows an accumulated deficit of EUR 383,419 thousand at the same date. The company says that, with the proceeds of this offering, it has "a projected cash runway through 2029." It names proof-of-concept readouts in aHUS, IgAN and C3G and a Phase 2 readout in AAV as the milestones that runway is meant to reach. The runway figure is the company's own projection, and the figures above show the cash base it would start from. The prospectus also discloses that Dr. Camilla Chong has resigned as Chief Medical Officer to pursue personal interests, effective August 2026. The company says the resignation was not the result of a disagreement over operations, policies or clinical programs, and that her responsibilities have been assumed by the existing clinical team and senior management, supported by external advisors. The filing does not name a replacement. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story IFRX InflaRx N.V. NASDAQ · Germany Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "InflaRx prices $150,000,000 share offering at $2.00", 2026-05-06, https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/